Lanean...
Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
Antibodies targeting the PD-1/PD-L1 immune checkpoint achieved spectacular success in anticancer therapy in the recent years. In contrast, no small molecules with cellular activity have been reported so far. Here we provide evidence that small molecules are capable of alleviating the PD-1/PD-L1 immu...
Gorde:
Argitaratua izan da: | Oncotarget |
---|---|
Egile Nagusiak: | , , , , , , , , , , , , , , |
Formatua: | Artigo |
Hizkuntza: | Inglês |
Argitaratua: |
Impact Journals LLC
2017
|
Gaiak: | |
Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5641120/ https://ncbi.nlm.nih.gov/pubmed/29069777 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20050 |
Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|